TNF and hepatocellular carcinoma: Current studies show that HCC can reduce serum TNF-α and plasma TXB2 levels and increase plasma 6-keto-PGF1α levels in IS patients, suggesting that its therapeutic effect may be related to regulation of vascular endothelial/platelet function balance [11, 12].